Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILES Trial: Sirolimus in Lymphangioleiomyomatosis
jRCT2091220011Phase 3Completed
- Sponsor
- Frank McCormack, M.D., University of Cincinnati Medical Center Director, Division of Pulmonary and Critical Care Medicine
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lymphangioleiomyomatosis (LAM) comparing Sirolimus 2 mg QD with Placebo (2 arms). Primary endpoint: FEV1 response. Started Jun 2007; status: completed.
02
Drugs
sirolimus
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on jRCT2091220011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220011.